AIP
VERV

Ameritas Investment Partners’s Verve Therapeutics VERV Stock Holding History

Ameritas Investment Partners’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,570
Closed -$73.8K – 3216
2025
Q2 		$73.8K Hold
6,570
– – ﹤0.01% 1940
2025
Q1 		$30K Hold
6,570
– – ﹤0.01% 2381
2024
Q4 		$37.1K Hold
6,570
– – ﹤0.01% 2361
2024
Q3 		$31.8K Hold
6,570
– – ﹤0.01% 2430
2024
Q2 		$32.1K Hold
6,570
– – ﹤0.01% 2381
2024
Q1 		$87.3K Buy
6,570
+1,530
+30% +$20.3K ﹤0.01% 1822
2023
Q4 		$70.3K Hold
5,040
– – ﹤0.01% 1960
2023
Q3 		$66.8K Buy
5,040
+851
+20% +$13.7K ﹤0.01% 1923
2023
Q2 		$78.5K Buy
4,189
+622
+17% +$10.4K ﹤0.01% 1755
2023
Q1 		$51.4K Hold
3,567
– – ﹤0.01% 1961
2022
Q4 		$80.6K Hold
3,567
– – ﹤0.01% 1743
2022
Q3 		$122K Buy
3,567
+740
+26% +$23.6K 0.01% 1360
2022
Q2 		$43K Hold
2,827
– – ﹤0.01% 2090
2022
Q1 		$65K Buy
2,827
+1,616
+133% +$46.2K ﹤0.01% 1909
2021
Q4 		$45K Hold
1,211
– – ﹤0.01% 2195
2021
Q3 		$57K Buy
+1,211
New +$71.2K ﹤0.01% 2072

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Ameritas Investment Partners's VERV Position: Q3 2025 in Review

Ameritas Investment Partners sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 6,570 shares — an estimated $73.8K sold.

Ameritas Investment Partners first reported a position in VERV in Q3 2021 and held it in 16 quarters. The position peaked at $122K in Q3 2022. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Ameritas Investment Partners reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Ameritas Investment Partners sold 6,570 Verve Therapeutics shares in Q3 2025, an estimated $73.8K.
  • Ameritas Investment Partners first reported a position in Verve Therapeutics in Q3 2021 and held it in 16 quarters.
  • Ameritas Investment Partners's Verve Therapeutics position peaked at $122K in Q3 2022.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Ameritas Investment Partners's 13F filing for Q3 2025, filed 10 Nov 2025.